Analysis and verification of the HMGB1 signaling pathway

被引:52
作者
Gong, Haijun [1 ]
Zuliani, Paolo [1 ]
Komuravelli, Anvesh [1 ]
Faeder, James R. [2 ]
Clarke, Edmund M. [1 ]
机构
[1] Carnegie Mellon Univ, Dept Comp Sci, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Dept Computat Biol, Pittsburgh, PA 15260 USA
基金
美国国家科学基金会;
关键词
MOBILITY GROUP BOX-1; CHROMATIN PROTEIN HMGB1; CELL-ACTIVATION; CDK INHIBITORS; MODEL CHECKING; P53; CANCER; AKT; RECEPTOR; RELEASE;
D O I
10.1186/1471-2105-11-S7-S10
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: Recent studies have found that overexpression of the High-mobility group box-1 (HMGB1) protein, in conjunction with its receptors for advanced glycation end products (RAGEs) and toll-like receptors (TLRs), is associated with proliferation of various cancer types, including that of the breast and pancreatic. Results: We have developed a rule-based model of crosstalk between the HMGB1 signaling pathway and other key cancer signaling pathways. The model has been simulated using both ordinary differential equations (ODEs) and discrete stochastic simulation. We have applied an automated verification technique, Statistical Model Checking, to validate interesting temporal properties of our model. Conclusions: Our simulations show that, if HMGB1 is overexpressed, then the oncoproteins CyclinD/E, which regulate cell proliferation, are overexpressed, while tumor suppressor proteins that regulate cell apoptosis (programmed cell death), such as p53, are repressed. Discrete, stochastic simulations show that p53 and MDM2 oscillations continue even after 10 hours, as observed by experiments. This property is not exhibited by the deterministic ODE simulation, for the chosen parameters. Moreover, the models also predict that mutations of RAS, ARF and P21 in the context of HMGB1 signaling can influence the cancer cell's fate - apoptosis or survival - through the crosstalk of different pathways.
引用
收藏
页数:13
相关论文
共 61 条
[1]  
Alon U, 2007, INTRO SYSTEMS BIOL D
[2]   AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth [J].
Altomare, DA ;
Wang, HQ ;
Skele, KL ;
De Rienzo, A ;
Klein-Szanto, AJ ;
Godwin, AK ;
Testa, JR .
ONCOGENE, 2004, 23 (34) :5853-5857
[3]  
[Anonymous], 2008, Computational Modeling of Gene Regulatory Networks-A Primer
[4]  
[Anonymous], 2002, LNCS
[5]   MDM2 EXPRESSION IS INDUCED BY WILD TYPE-P53 ACTIVITY [J].
BARAK, Y ;
JUVEN, T ;
HAFFNER, R ;
OREN, M .
EMBO JOURNAL, 1993, 12 (02) :461-468
[6]   Pancreatic cancer biology and genetics [J].
Bardeesy, N ;
DePinho, RA .
NATURE REVIEWS CANCER, 2002, 2 (12) :897-909
[7]   PTEN, more than the AKT pathway [J].
Blanco-Aparicio, Carmen ;
Renner, Oliver ;
Leal, Juan F. M. ;
Carnero, Amancio .
CARCINOGENESIS, 2007, 28 (07) :1379-1386
[8]   Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion [J].
Bonaldi, T ;
Talamo, F ;
Scaffidi, P ;
Ferrera, D ;
Porto, A ;
Bachi, A ;
Rubartelli, A ;
Agresti, A ;
Bianchi, ME .
EMBO JOURNAL, 2003, 22 (20) :5551-5560
[9]   Analysis of a minimal model for p53 oscillations [J].
Bottani, Samuel ;
Grammaticos, Basile .
JOURNAL OF THEORETICAL BIOLOGY, 2007, 249 (02) :235-245
[10]   HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma [J].
Brezniceanu, ML ;
Völp, K ;
Bösse, S ;
Solbach, C ;
Lichter, P ;
Joos, S ;
Zörnig, M .
FASEB JOURNAL, 2003, 17 (08) :1295-+